Cargando…
Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to...
Autores principales: | Cheon, Yun-Hong, Kim, Moon Jin, Kang, Min Gyu, Kim, Hee Jin, Lee, Sang Su, Kim, Cha Young, Jeon, Dae-Hong, Kim, Yu Eun, Lee, Gyeong-Won |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Yonsei University College of Medicine
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104451/ https://www.ncbi.nlm.nih.gov/pubmed/21623617 http://dx.doi.org/10.3349/ymj.2011.52.4.695 |
Ejemplares similares
-
Inflammatory Fibroid Polyp in the Jejunum Causing Small Bowel Intussusception
por: Kang, Sung Hoon, et al.
Publicado: (2015) -
Carcinosarcoma on Ascending Colon Found by Bowel Perforation: A Case Report
por: Shim, Hong Jin, et al.
Publicado: (2010) -
Case of Small Bowel Perforation due to Enteropathy-Type T-Cell Lymphoma
por: Kim, Yong Seok, et al.
Publicado: (2009) -
Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013) -
Experience of serious intestinal hemorrhage and perforation in small bowel lymphoma: a case report
por: Kim, Seo Ree, et al.
Publicado: (2021)